

Javier Martinez-Picado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4749189/publications.pdf>

Version: 2024-02-01

233
papers

17,334
citations

20759

60
h-index

17055

122
g-index

241
all docs

241
docs citations

241
times ranked

19389
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,983
2	A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. <i>Science</i> , 2007, 317, 944-947.	6.0	1,136
3	HIV evolution: CTL escape mutation and reversion after transmission. <i>Nature Medicine</i> , 2004, 10, 282-289.	15.2	769
4	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. <i>Nature Medicine</i> , 2010, 16, 460-465.	15.2	500
5	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012, 12, 607-614.	10.6	485
6	HIV-1 remission following CCR5 Δ 32 haematopoietic stem-cell transplantation. <i>Nature</i> , 2019, 568, 244-248.	13.7	447
7	Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2006, 80, 3617-3623.	1.5	408
8	Common Genetic Variation and the Control of HIV-1 in Humans. <i>PLoS Genetics</i> , 2009, 5, e1000791.	1.5	377
9	Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 1999, 73, 3744-3752.	1.5	373
10	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. <i>Science Immunology</i> , 2021, 6, .	5.6	357
11	Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. <i>Lancet, The</i> , 2013, 381, 2109-2117.	6.3	275
12	Immune Selection for Altered Antigen Processing Leads to Cytotoxic T Lymphocyte Escape in Chronic HIV-1 Infection. <i>Journal of Experimental Medicine</i> , 2004, 199, 905-915.	4.2	266
13	Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. <i>Journal of Virology</i> , 2014, 88, 10056-10065.	1.5	242
14	Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. <i>Nature</i> , 2021, 598, 342-347.	13.7	230
15	Human genetic and immunological determinants of critical COVID-19 pneumonia. <i>Nature</i> , 2022, 603, 587-598.	13.7	216
16	Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. <i>Blood</i> , 2009, 113, 2732-2741.	0.6	208
17	Siglec-1 Is a Novel Dendritic Cell Receptor That Mediates HIV-1 Trans-Infection Through Recognition of Viral Membrane Gangliosides. <i>PLoS Biology</i> , 2012, 10, e1001448.	2.6	208
18	Antiretroviral resistance during successful therapy of HIV type 1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 10948-10953.	3.3	205

#	ARTICLE	IF	CITATIONS
19	Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. <i>Aids</i> , 2000, 14, 2857-2867.	1.0	194
20	A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication. <i>Science Translational Medicine</i> , 2013, 5, 166ra2.	5.8	193
21	Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. <i>Aids</i> , 2000, 14, 397-403.	1.0	189
22	HIV and Mature Dendritic Cells: Trojan Exosomes Riding the Trojan Horse?. <i>PLoS Pathogens</i> , 2010, 6, e1000740.	2.1	184
23	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. <i>Journal of Clinical Investigation</i> , 2011, 121, 2391-2400.	3.9	168
24	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14658-14663.	3.3	154
25	Evidence for HIV-1 cure after CCR5 Δ 32/32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. <i>Lancet HIV</i> , 2020, 7, e340-e347.	2.1	151
26	Definition of the viral targets of protective HIV-1-specific T cell responses. <i>Journal of Translational Medicine</i> , 2011, 9, 208.	1.8	143
27	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. <i>Lancet HIV</i> , 2019, 6, e259-e268.	2.1	139
28	HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. <i>Aids</i> , 2001, 15, F19-F27.	1.0	135
29	Persistent HIV-1 replication during antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 417-423.	1.5	133
30	Copy Number Variation of KIR Genes Influences HIV-1 Control. <i>PLoS Biology</i> , 2011, 9, e1001208.	2.6	132
31	Cell entry and export of nucleoside analogues. <i>Virus Research</i> , 2005, 107, 151-164.	1.1	127
32	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. <i>ELife</i> , 2013, 2, e01123.	2.8	126
33	HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo. <i>Virus Research</i> , 2008, 134, 104-123.	1.1	125
34	Transport of Lamivudine [(2S,3S)-2,3-Dideoxy-3-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 252-261.	1.3	125
35	Efficacy of Low-Dose Subcutaneous Interleukin-2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with $\geq 1/4$ CD4 T Cells and Undetectable Plasma Virus Load. <i>Journal of Infectious Diseases</i> , 1999, 180, 56-60.	1.9	110
36	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	3.3	110

#	ARTICLE	IF	CITATIONS
37	Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls. <i>PLoS Pathogens</i> , 2013, 9, e1003515.	2.1	109
38	Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study. <i>Antiviral Therapy</i> , 2012, 17, 355-364.	0.6	108
39	HIV-1 Capture and Transmission by Dendritic Cells: The Role of Viral Glycolipids and the Cellular Receptor Siglec-1. <i>PLoS Pathogens</i> , 2014, 10, e1004146.	2.1	108
40	A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 473-478.	1.9	105
41	CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	105
42	Maturation of Blood-Derived Dendritic Cells Enhances Human Immunodeficiency Virus Type 1 Capture and Transmission. <i>Journal of Virology</i> , 2007, 81, 7559-7570.	1.5	99
43	Infrequent Recovery of HIV from but Robust Exogenous Infection of Activated CD4 ⁺ T Cells in HIV Elite Controllers. <i>Clinical Infectious Diseases</i> , 2010, 51, 233-238.	2.9	98
44	Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2015, 61, 1169-1178.	2.9	97
45	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. <i>Nature Medicine</i> , 2020, 26, 1339-1350.	15.2	96
46	Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. <i>Aids</i> , 2002, 16, 1009-1017.	1.0	92
47	Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. <i>Aids</i> , 2002, 16, 895-899.	1.0	85
48	HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells. <i>Retrovirology</i> , 2015, 12, 37.	0.9	85
49	Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. <i>Journal of Experimental Medicine</i> , 2006, 203, 529-539.	4.2	81
50	Sialyllactose in Viral Membrane Gangliosides Is a Novel Molecular Recognition Pattern for Mature Dendritic Cell Capture of HIV-1. <i>PLoS Biology</i> , 2012, 10, e1001315.	2.6	78
51	Dihydrospingomyelin Impairs HIV-1 Infection by Rigidifying Liquid-Ordered Membrane Domains. <i>Chemistry and Biology</i> , 2010, 17, 766-775.	6.2	76
52	Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. <i>Aids</i> , 2007, 21, 169-178.	1.0	74
53	Exosomes and retroviruses: the chicken or the egg?. <i>Cellular Microbiology</i> , 2011, 13, 10-17.	1.1	71
54	HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics. <i>PLoS ONE</i> , 2012, 7, e40198.	1.1	71

#	ARTICLE	IF	CITATIONS
55	Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection. <i>JAMA Oncology</i> , 2020, 6, 1063.	3.4	70
56	Transcriptional Profiling of CD4 T Cells Identifies Distinct Subgroups of HIV-1 Elite Controllers. <i>Journal of Virology</i> , 2011, 85, 3015-3019.	1.5	69
57	Fitness of Human Immunodeficiency Virus Type 1 Protease Inhibitor-Selected Single Mutants. <i>Virology</i> , 2000, 275, 318-322.	1.1	68
58	Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3080-3086.	1.3	68
59	Role of Structured Treatment Interruption before a 5â€Drug Salvage Antiretroviral Regimen: The Retrogene Study. <i>Journal of Infectious Diseases</i> , 2003, 188, 977-985.	1.9	66
60	Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 558-567.	1.3	66
61	Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. <i>Aids</i> , 2018, 32, 2533-2545.	1.0	65
62	Drug uptake transporters in antiretroviral therapy. , 2011, 132, 268-279.		62
63	Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. <i>Aids</i> , 2014, 28, 325-334.	1.0	62
64	Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. <i>Annals of Internal Medicine</i> , 2018, 169, 674.	2.0	59
65	Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resourceâ€Limited Settings. <i>Journal of Infectious Diseases</i> , 2009, 200, 687-697.	1.9	56
66	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1833-1842.	1.3	56
67	Plasma-derived extracellular vesicles from <i>Plasmodium vivax</i> patients signal spleen fibroblasts via NF- κ B facilitating parasite cytoadherence. <i>Nature Communications</i> , 2020, 11, 2761.	5.8	56
68	Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART. <i>PLoS Pathogens</i> , 2011, 7, e1002314.	2.1	55
69	Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. <i>Aids</i> , 2013, 27, 81-85.	1.0	55
70	Effect of an Electrolyte Additive of Vinylene Carbonate on the Electronic Structure at the Surface of a Lithium Cobalt Oxide Electrode under Battery Operating Conditions. <i>Journal of Physical Chemistry C</i> , 2015, 119, 9791-9797.	1.5	55
71	HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). <i>Frontiers in Immunology</i> , 2020, 11, 823.	2.2	55
72	Functional Consequences of Human Immunodeficiency Virus Escape from an HLA-B*13-Restricted CD8+ T-Cell Epitope in p1 Gag Protein. <i>Journal of Virology</i> , 2009, 83, 1018-1025.	1.5	54

#	ARTICLE	IF	CITATIONS
73	Resistance to Protease Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26 Suppl 1, S34-S50.	0.9	53
74	Viral Dynamics during Structured Treatment Interruptions of Chronic Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2002, 76, 968-979.	1.5	52
75	CCR5 Δ 32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report. <i>Lancet HIV</i> , 2015, 2, e236-e242.	2.1	52
76	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). <i>EClinicalMedicine</i> , 2019, 11, 65-80.	3.2	52
77	A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9981-9990.	3.3	51
78	Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation. <i>Journal of Virology</i> , 2016, 90, 6148-6158.	1.5	50
79	Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue. <i>PLoS ONE</i> , 2017, 12, e0175899.	1.1	50
80	Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. <i>Scientific Reports</i> , 2020, 10, 1902.	1.6	50
81	Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. <i>Journal of Virological Methods</i> , 2006, 136, 102-117.	1.0	47
82	HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. <i>Retrovirology</i> , 2008, 5, 32.	0.9	46
83	Contribution of Immunological and Virological Factors to Extremely Severe Primary HIV Type 1 Infection. <i>Clinical Infectious Diseases</i> , 2009, 48, 229-238.	2.9	44
84	Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. <i>Aids</i> , 2012, 26, 2285-2293.	1.0	44
85	Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry. <i>Nature Microbiology</i> , 2019, 4, 1558-1570.	5.9	44
86	A medium for presumptive identification of <i>Vibrio anguillarum</i> . <i>Applied and Environmental Microbiology</i> , 1994, 60, 1681-1683.	1.4	43
87	Alternation of Antiretroviral Drug Regimens for HIV Infection. <i>Annals of Internal Medicine</i> , 2003, 139, 81.	2.0	42
88	Capture of cell-derived microvesicles (exosomes and apoptotic bodies) by human plasmacytoid dendritic cells. <i>Journal of Leukocyte Biology</i> , 2012, 91, 751-758.	1.5	42
89	Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen. <i>Aids</i> , 2006, 20, 2075-2080.	1.0	41
90	Modelling HIV-1 2-LTR dynamics following raltegravir intensification. <i>Journal of the Royal Society Interface</i> , 2013, 10, 20130186.	1.5	39

#	ARTICLE	IF	CITATIONS
91	Post COVID-19 Condition in Children and Adolescents: An Emerging Problem. <i>Frontiers in Pediatrics</i> , 2022, 10, .	0.9	39
92	Interaction of Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with the Concentrative Nucleoside Transporter-1 (Slc28A1). <i>Antiviral Therapy</i> , 2004, 9, 993-1002.	0.6	39
93	The infectious synapse formed between mature dendritic cells and CD4+T cells is independent of the presence of the HIV-1 envelope glycoprotein. <i>Retrovirology</i> , 2013, 10, 42.	0.9	38
94	A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. <i>Human Molecular Genetics</i> , 2013, 22, 1903-1910.	1.4	38
95	Mouse Siglec-1 Mediates trans-Infection of Surface-bound Murine Leukemia Virus in a Sialic Acid N-Acyl Side Chain-dependent Manner. <i>Journal of Biological Chemistry</i> , 2015, 290, 27345-27359.	1.6	38
96	Identification of Siglec-1 null individuals infected with HIV-1. <i>Nature Communications</i> , 2016, 7, 12412.	5.8	38
97	Human Immunodeficiency Virus Type 1 Cloning Vectors for Antiretroviral Resistance Testing. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2943-2951.	1.8	38
98	A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy. <i>Journal of General Virology</i> , 2003, 84, 2217-2228.	1.3	37
99	Fitness Variations and their Impact on the Evolution of Antiretroviral Drug Resistance. <i>Current Drug Targets Infectious Disorders</i> , 2003, 3, 355-371.	2.1	37
100	Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4 ⁺ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016, 213, 1008-1012.	1.9	36
101	Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. <i>Journal of the International AIDS Society</i> , 2017, 20, 21171.	1.2	36
102	SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2676-2678.	4.8	36
103	Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. <i>Virology</i> , 2004, 326, 103-112.	1.1	35
104	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. <i>Science Immunology</i> , 2023, 8, .	5.6	35
105	Detailed Characterization of Early HIV-1 Replication Dynamics in Primary Human Macrophages. <i>Viruses</i> , 2018, 10, 620.	1.5	34
106	The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates. <i>Aids</i> , 2010, 24, 17-25.	1.0	33
107	Dynamic Imaging of Cell-Free and Cell-Associated Viral Capture in Mature Dendritic Cells. <i>Traffic</i> , 2011, 12, 1702-1713.	1.3	32
108	Proteomics study of human cord blood reticulocyte-derived exosomes. <i>Scientific Reports</i> , 2018, 8, 14046.	1.6	32

#	ARTICLE	IF	CITATIONS
109	The PDZ-adaptor protein syntenin-1 regulates HIV-1 entry. <i>Molecular Biology of the Cell</i> , 2012, 23, 2253-2263.	0.9	31
110	Comparison of Sequencing by Hybridization and Cycle Sequencing for Genotyping of Human Immunodeficiency Virus Type 1 Reverse Transcriptase. <i>Journal of Clinical Microbiology</i> , 2000, 38, 2715-2721.	1.8	31
111	Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages. <i>ELife</i> , 2020, 9, .	2.8	31
112	Dendritic Cells From the Cervical Mucosa Capture and Transfer HIV-1 via Siglec-1. <i>Frontiers in Immunology</i> , 2019, 10, 825.	2.2	30
113	Mechanisms Involved in the Selection of HIV-1 Reverse Transcriptase Thumb Subdomain Polymorphisms Associated with Nucleoside Analogue Therapy Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4799-4811.	1.4	29
114	Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence. <i>Retrovirology</i> , 2018, 15, 15.	0.9	29
115	Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300–106/l. <i>Aids</i> , 1996, 10, F39-F44.	1.0	28
116	Prevalence of HIV Protease Mutations on Failure of Nelfinavir-Containing HAART: A Retrospective Analysis of Four Clinical Studies and Two Observational Cohorts. <i>HIV Clinical Trials</i> , 2002, 3, 316-323.	2.0	28
117	Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. <i>Antiviral Research</i> , 2010, 88, 281-286.	1.9	28
118	Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2358-2362.	1.3	28
119	Actin-binding Protein Drebrin Regulates HIV-1-triggered Actin Polymerization and Viral Infection. <i>Journal of Biological Chemistry</i> , 2013, 288, 28382-28397.	1.6	28
120	Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e114142.	1.1	27
121	Viral Evolution during Structured Treatment Interruptions in Chronically Human Immunodeficiency Virus-Infected Individuals. <i>Journal of Virology</i> , 2002, 76, 12344-12348.	1.5	26
122	Lack of Longitudinal Inpatient Correlation between p24 Antigenemia and Levels of Human Immunodeficiency Virus (HIV) Type 1 RNA in Patients with Chronic HIV Infection during Structured Treatment Interruptions. <i>Journal of Clinical Microbiology</i> , 2004, 42, 1620-1625.	1.8	26
123	Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. <i>Vaccines</i> , 2019, 7, 209.	2.1	25
124	When Dendritic Cells Go Viral: The Role of Siglec-1 in Host Defense and Dissemination of Enveloped Viruses. <i>Viruses</i> , 2020, 12, 8.	1.5	25
125	Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control. <i>PLoS Pathogens</i> , 2020, 16, e1008678.	2.1	25
126	HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. <i>Journal of Infectious Diseases</i> , 2016, 214, 1512-1519.	1.9	24

#	ARTICLE	IF	CITATIONS
127	Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005, 77, 23-28.	2.5	23
128	Relative Fitness and Replication Capacity of a Multinucleoside Analogue-Resistant Clinical Human Immunodeficiency Virus Type 1 Isolate with a Deletion of Codon 69 in the Reverse Transcriptase Coding Region. <i>Journal of Virology</i> , 2007, 81, 4713-4721.	1.5	23
129	Impact of Phenotype Definition on Genome-Wide Association Signals: Empirical Evaluation in Human Immunodeficiency Virus Type 1 Infection. <i>American Journal of Epidemiology</i> , 2011, 173, 1336-1342.	1.6	23
130	Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals. <i>Clinical Infectious Diseases</i> , 2019, 69, 1320-1328.	2.9	23
131	HIGH-FREQUENCY failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal needs causing maternal NON-ADHERENCE. <i>EClinicalMedicine</i> , 2020, 22, 100344.	3.2	23
132	HIV Type 1 Fitness Evolution in Antiretroviral-Experienced Patients with Sustained CD4+ T Cell Counts but Persistent Virologic Failure. <i>Clinical Infectious Diseases</i> , 2005, 41, 729-737.	2.9	22
133	Optimal Antiviral Switching to Minimize Resistance Risk in HIV Therapy. <i>PLoS ONE</i> , 2011, 6, e27047.	1.1	22
134	Cancer immunotherapy of patients with HIV infection. <i>Clinical and Translational Oncology</i> , 2019, 21, 713-720.	1.2	22
135	Raltegravir Susceptibility and Fitness Progression of HIV Type-1 Integrase in Patients on Long-Term Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2008, 13, 881-893.	0.6	22
136	HIV-1 Capture and Antigen Presentation by Dendritic Cells: Enhanced Viral Capture Does Not Correlate with Better T Cell Activation. <i>Journal of Immunology</i> , 2012, 188, 6036-6045.	0.4	21
137	Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 152-160.	0.9	21
138	Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors. <i>British Journal of Pharmacology</i> , 2014, 171, 3868-3880.	2.7	21
139	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. <i>Aids</i> , 2015, 29, 2323-2333.	1.0	21
140	Variability in the Plasma Concentration of Efavirenz and Nevirapine is Associated with Genotypic Resistance after Treatment Interruption. <i>Antiviral Therapy</i> , 2008, 13, 945-951.	0.6	21
141	Efficacy of Adding Indinavir to Previous Reverse Transcriptase Nucleoside Analogues in Relation to Genotypic and Phenotypic Resistance Development in Advanced HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 19-28.	0.3	20
142	Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 2089.	1.0	20
143	A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 741-752.	1.9	19
144	Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1940-1948.	1.3	19

#	ARTICLE	IF	CITATIONS
145	Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report. <i>Lancet Microbe</i> , The, 2020, 1, e130-e135.	3.4	19
146	Gut microbiome signatures linked to HIV-1 reservoir size and viremia control. <i>Microbiome</i> , 2022, 10, 59.	4.9	19
147	Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC. <i>Aids</i> , 1996, 10, F61-F66.	1.0	18
148	Random T-Cell Receptor Recruitment in Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8 ⁺ T Cells from Genetically Identical Twins Infected with the Same HIV-1 Strain. <i>Journal of Virology</i> , 2007, 81, 12666-12669.	1.5	18
149	Mechanistic Basis of Zidovudine Hypersusceptibility and Lamivudine Resistance Conferred by the Deletion of Codon 69 in the HIV-1 Reverse Transcriptase Coding Region. <i>Journal of Molecular Biology</i> , 2008, 382, 327-341.	2.0	18
150	Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. <i>Aids</i> , 2014, 28, 1261-1272.	1.0	18
151	Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch. <i>HIV Medicine</i> , 2015, 16, 388-392.	1.0	18
152	Identification of Interleukin-27 (IL-27)/IL-27 Receptor Subunit Alpha as a Critical Immune Axis for <i>In Vivo</i> HIV Control. <i>Journal of Virology</i> , 2017, 91, .	1.5	18
153	Extremely low viral reservoir in treated chronically HIV-1-infected individuals. <i>EBioMedicine</i> , 2020, 57, 102830.	2.7	18
154	³ â€²-Azido-2â€²,3â€²-Dideoxythymidine (Zidovudine) Uptake Mechanisms in T Lymphocytes. <i>Antiviral Therapy</i> , 2006, 11, 803-812.	0.6	18
155	Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4 ⁺ T cells of antiretroviral therapy suppressed patients. <i>Aids</i> , 2014, 28, 2157-2159.	1.0	17
156	Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8 ⁺ T Cells Limit the Killing of HIV-1 Reactivated Cells. <i>Frontiers in Immunology</i> , 2019, 9, 3162.	2.2	17
157	Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	17
158	P-glycoprotein (<i>ABC1</i>) activity decreases raltegravir disposition in primary CD4 ⁺ -gp ^{high} cells and correlates with HIV-1 viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2782-2792.	1.3	16
159	Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. <i>Frontiers in Pharmacology</i> , 2016, 7, 175.	1.6	16
160	Influence of Prior Structured Treatment Interruptions on the Length of Time without Antiretroviral Treatment in Chronically HIV-Infected Subjects. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 1283-1288.	0.5	15
161	AM3 Modulates Dendritic Cell Pathogen Recognition Capabilities by Targeting DC-SIGN. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2313-2323.	1.4	15
162	Attacking the HIV Reservoir from the Immune and Viral Perspective. <i>Current HIV/AIDS Reports</i> , 2013, 10, 33-41.	1.1	15

#	ARTICLE	IF	CITATIONS
163	Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection. <i>Nature Communications</i> , 2020, 11, 1767.	5.8	15
164	Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e87334.	1.1	15
165	Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2005, 79, 5907-5913.	1.5	14
166	Thymidine Analogue Excision and Discrimination Modulated by Mutational Complexes Including Single Amino Acid Deletions of Asp-67 or Thr-69 in HIV-1 Reverse Transcriptase. <i>Journal of Biological Chemistry</i> , 2011, 286, 20615-20624.	1.6	14
167	Lack of concordance between residual viremia and viral variants driving de novo infection of CD4+ T cells on ART. <i>Retrovirology</i> , 2016, 13, 51.	0.9	14
168	Retroviruses As Myeloid Cell Riders: What Natural Human Siglec-1 Knockouts Tell Us About Pathogenesis. <i>Frontiers in Immunology</i> , 2017, 8, 1593.	2.2	14
169	Differential Immunodominance Hierarchy of CD8 ⁺ T-Cell Responses in HLA-B*27:05- and -B*27:02-Mediated Control of HIV-1 Infection. <i>Journal of Virology</i> , 2018, 92, .	1.5	14
170	Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2501-2501.	0.8	14
171	In-depth Characterization of Viral Isolates from Plasma and Cells Compared with Plasma Circulating Quasispecies in Early HIV-1 Infection. <i>PLoS ONE</i> , 2012, 7, e32714.	1.1	14
172	Assessing main death pathways in T lymphocytes from HIV infected individuals. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83A, 648-658.	1.1	13
173	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3087-3095.	1.3	13
174	Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors. <i>Scientific Reports</i> , 2017, 7, 3717.	1.6	13
175	Dasatinib protects humanized mice from acute HIV-1 infection. <i>Biochemical Pharmacology</i> , 2020, 174, 113625.	2.0	13
176	The Genome-wide Methylation Profile of CD4+ T Cells From Individuals With Human Immunodeficiency Virus (HIV) Identifies Distinct Patterns Associated With Disease Progression. <i>Clinical Infectious Diseases</i> , 2021, 72, e256-e264.	2.9	13
177	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. <i>PLoS ONE</i> , 2017, 12, e0184929.	1.1	13
178	Short Communication: Naive CD4+ T Cells and Recent Thymic Emigrant Levels in Treated Individuals with HIV: Clinical Relevance. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 893-896.	0.5	12
179	Effect of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Polymorphism Leu-214 on Replication Capacity and Drug Susceptibility. <i>Journal of Virology</i> , 2009, 83, 7434-7439.	1.5	12
180	Combined Antiretroviral Therapy and Immune Pressure Lead to In Vivo HIV-1 Recombination With Ancestral Viral Genomes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 109-117.	0.9	12

#	ARTICLE	IF	CITATIONS
181	HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA: Diagnostic Accuracy, Viral Evolution and Compartmentalization. PLoS ONE, 2013, 8, e67085.	1.1	12
182	Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. Scientific Reports, 2017, 7, 40800.	1.6	12
183	An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults. PLoS Pathogens, 2021, 17, e1010090.	2.1	12
184	Improved CD4 Lymphocyte Outgrowth in Response to Effective Antiretroviral Therapy. Journal of Infectious Diseases, 1999, 179, 345-351.	1.9	11
185	Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus-related Lymphomas. Clinical Infectious Diseases, 2019, 68, 834-843.	2.9	11
186	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)., 2021, 9, e001664.		11
187	Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish elite control in adolescents living with HIV from viremic nonprogressors. Aids, 2022, 36, 95-105.	1.0	11
188	Atlas of the HIV-1 Reservoir in Peripheral CD4 T Cells of Individuals on Successful Antiretroviral Therapy. MBio, 2021, 12, e0307821.	1.8	11
189	Comparative Analysis of HIV Type 1 Genotypic Resistance across Antiretroviral Trial Treatment Regimens. AIDS Research and Human Retroviruses, 2000, 16, 1325-1336.	0.5	10
190	HIV integrase inhibitors in ART-experienced patients. Current Opinion in HIV and AIDS, 2012, 7, 415-421.	1.5	10
191	Dynamics of the Decay of Human Immunodeficiency Virus (HIV) RNA and Distribution of Bictegravir in the Genital Tract and Rectum in Antiretroviral-naïve Adults Living With HIV-1 Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (Spanish HIV/AIDS Research Network, PreEC/RIS 58). Clinical Infectious Diseases, 2021, 73, e1991-e1999.	2.9	10
192	Evolution of HIV drug Resistance in Zidovudine/Zalcitabine- and Zidovudine/ Didanosine-Experienced Patients Receiving Lamivudine-Containing Combination Therapy. Antiviral Therapy, 1998, 3, 81-88.	0.6	10
193	Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. Vaccine, 2011, 29, 5711-5724.	1.7	9
194	Dissemination of <i>Mycobacterium tuberculosis</i> is associated to a <i>SIGLEC1</i> null variant that limits antigen exchange via trafficking extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12046.	5.5	9
195	Early Initiation of Antiretroviral Therapy Following In Utero HIV Infection Is Associated With Low Viral Reservoirs but Other Factors Determine Viral Rebound. Journal of Infectious Diseases, 2021, 224, 1925-1934.	1.9	9
196	VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies. MBio, 2021, 12, e0056021.	1.8	9
197	Alternation of Antiretroviral Drug Regimens for HIV Infection. Efficacy, Safety and Tolerability at Week 96 of the Swatch Study. Antiviral Therapy, 2004, 9, 889-893.	0.6	9
198	Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1 infected patients with multidrug-resistant virus: a multicentre pilot study. HIV Medicine, 2008, 9, 508-513.	1.0	8

#	ARTICLE	IF	CITATIONS
199	Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. <i>Biochemical Pharmacology</i> , 2021, 192, 114666.	2.0	8
200	Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy. <i>Antiviral Therapy</i> , 2008, 13, 881-93.	0.6	8
201	The Status of the Alfalfa Snout Beetle in New York State ¹ . <i>Journal of Economic Entomology</i> , 1971, 64, 1332-1333.	0.8	7
202	Transient Treatment Exclusively Containing Nucleoside Analogue Reverse Transcriptase Inhibitors in Highly Antiretroviral-Experienced Patients Preserves Viral Benefit When a Fully Active Therapy Was Initiated. <i>HIV Clinical Trials</i> , 2008, 9, 387-398.	2.0	7
203	A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 32-38.	1.3	7
204	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012, 9, 68.	0.9	7
205	Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses. <i>Journal of Virology</i> , 2018, 92, .	1.5	7
206	HIV-1 DNA decay dynamics in early treated individuals: practical considerations for clinical trial design. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2258-2263.	1.3	7
207	Motivations, barriers and experiences of participants in an HIV reservoir trial. <i>Journal of Virus Eradication</i> , 2021, 7, 100029.	0.3	7
208	ABX464 Decreases the Total Human Immunodeficiency Virus (HIV) Reservoir and HIV Transcription Initiation in CD4+ T Cells From Antiretroviral Therapyâ€“Suppressed Individuals Living With HIV. <i>Clinical Infectious Diseases</i> , 2022, 74, 2044-2049.	2.9	7
209	Novel Two-Round Phenotypic Assay for Protease Inhibitor Susceptibility Testing of Recombinant and Primary HIV-1 Isolates. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3909-3916.	1.8	6
210	Increasing Diagnostic Uncertainties in Children With In Utero HIV Infection. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, e166-e168.	1.1	6
211	Altered Tâ€“cell subset distribution in the viral reservoir in HIVâ€“infected individuals with extremely low proviral DNA (LoViReTs). <i>Journal of Internal Medicine</i> , 2022, 292, 308-320.	2.7	6
212	New Macrocyclic Amines Showing Activity as HIV Entry Inhibitors Against Wild Type and Multi-Drug Resistant Viruses. <i>Molecules</i> , 2009, 14, 1927-1937.	1.7	5
213	Relationship between CCR5(WT/Î”32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection. <i>Clinical Microbiology and Infection</i> , 2017, 23, 318-324.	2.8	5
214	Response to â€“Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1â€“. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 360, 343-345.	1.3	5
215	Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome. <i>EBioMedicine</i> , 2022, 78, 103956.	2.7	5
216	Risk of selecting resistance mutations during treatment interruption. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 6-13.	1.5	4

#	ARTICLE	IF	CITATIONS
217	Drug-Resistance Mutations Number and K70R or T215Y/F Substitutions Predict Treatment Resumption during Guided Treatment Interruptions. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 725-732.	0.5	4
218	The Magnitude of Interferon- β Responses to Human Cytomegalovirus Is Predictive for HIV-1 Disease Progression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 507-512.	0.9	4
219	Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029. <i>Clinical Microbiology and Infection</i> , 2015, 21, 103.e1-103.e6.	2.8	4
220	Epstein-Barr viral loads and serum free light chains levels are potential follow-up markers of HIV-related lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 211-213.	0.6	4
221	Evidence for Preferential Genotyping of a Minority Human Immunodeficiency Virus Population Due to Primer-Template Mismatching during PCR-Based Amplification. <i>Journal of Clinical Microbiology</i> , 2005, 43, 436-438.	1.8	3
222	TL1A-Specific Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses. <i>Journal of Immunology</i> , 2020, 205, 3348-3357.	0.4	3
223	Transcriptional signature of resting-memory CD4 T cells differentiates spontaneous from treatment-induced HIV control. <i>Journal of Molecular Medicine</i> , 2020, 98, 1093-1105.	1.7	3
224	Communications: Iridovirus-like Particles Associated with Nodular Skin Lesions and Vesicles in <i>Parapercyptus serperaster</i> . <i>Journal of Aquatic Animal Health</i> , 1993, 5, 148-151.	0.6	3
225	Launching a multidisciplinary European collaboration towards a cure for HIV: The EU2Cure Consortium. <i>Journal of Virus Eradication</i> , 2021, 7, 100045.	0.3	2
226	Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1032-1040.	1.3	2
227	Past and future of HIV infection. A document based on expert opinion. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 131-156.	0.5	2
228	Long-term impact of antiretroviral strategies for a functional HIV cure: A virtual clinical trial. <i>IFAC-PapersOnLine</i> , 2018, 51, 80-85.	0.5	1
229	Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer Reply. <i>JAMA Oncology</i> , 2020, 6, 1810.	3.4	1
230	Monocyte-derived DC Electroporated with mRNAs Encoding Both Specific HIV Antigens and DC Adjuvants Are Able to Improve T-cell Functionality. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A194-A194.	0.5	0
231	Siglec-1 Expressed on Dendritic Cells is a New Receptor Implicated in Arenavirus Uptake. <i>Proceedings (mdpi)</i> , 2020, 50, 90.	0.2	0
232	Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors. <i>Journal of Virology</i> , 2022, 96, JVI0149921.	1.5	0
233	Next-generation point-of-care testing in pediatric human immunodeficiency virus infection facilitates diagnosis and monitoring of treatment. <i>Medicine (United States)</i> , 2022, 101, e29228.	0.4	0